FLT3-directed BiTE molecule

The FLT3-directed BiTE molecule is an investigational bispecific T-cell engager (BiTE) designed for the treatment of acute myeloid leukemia (AML). It is engineered to simultaneously bind to FMS-like tyrosine kinase 3 (FLT3, also known as CD135) on the surface of AML blasts and leukemic stem cells, and the CD3 epsilon subunit of the T-cell receptor complex on cytotoxic T cells. This dual binding brings T cells into close proximity with tumor cells, triggering T-cell activation and the release of perforins and granzymes, which results in the selective lysis of FLT3-expressing malignant cells. AMG 427 is the primary clinical candidate representing this molecule type, developed by Amgen, although its clinical development was terminated following early-phase trials.

Other names

FLT3 x CD3 BiTEFLT-3 x CD3 BiTEFLT 3 x CD3 BiTEFLT3-CD3 bispecific T-cell engagerFLT-3-CD3 bispecific T-cell engagerFLT 3-CD3 bispecific T-cell engager